MENU
XBI
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

XBI stock forecast, quote, news & analysis

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U... Show more

Category: #Health
XBI
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for XBI with price predictions
Sep 10, 2026

XBI in -3.16% downward trend, declining for three consecutive days on September 10, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XBI declined for three days, in 229 of 258 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for XBI moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In 79 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 46 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

XBI moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 291 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 229 of 251 cases where XBI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the State Street® SPDR® S&P® Biotech ETF ETF is 14.9B. The market cap for tickers in the group ranges from 35.24M to 454.36B. ABBV holds the highest valuation in this group at 454.36B. The lowest valued company is SCLX at 35.24M.

High and low price notable news

The average weekly price growth across all stocks in the State Street® SPDR® S&P® Biotech ETF ETF was 17%. For the same ETF, the average monthly price growth was 126%, and the average quarterly price growth was 195%. ROIV experienced the highest price growth at 19%, while RNA experienced the biggest fall at -29%.

Volume

The average weekly volume growth across all stocks in the State Street® SPDR® S&P® Biotech ETF ETF was 1%. For the same stocks of the ETF, the average monthly volume growth was 16% and the average quarterly volume growth was -40%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 69
Price Growth Rating: 45
SMR Rating: 85
Profit Risk Rating: 76
Seasonality Score: -16 (-100 ... +100)
View a ticker or compare two or three
XBI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com